<DOC>
	<DOC>NCT01819649</DOC>
	<brief_summary>This is a pilot study proceeding an intended international trial. Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast tablets will reduce the risk of cancer in healthy individuals. Objective: The objective of this pilot study was to assess the viability of a full scale randomised trial.</brief_summary>
	<brief_title>Selenium in the Prevention of Cancer</brief_title>
	<detailed_description />
	<mesh_term>Selenium</mesh_term>
	<criteria>WHO performance status 0 or 1 No active liver or kidney disease (Serum ALAT (alanine aminotransferase), alkalic phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range) No previous cancer diagnosis No known HIVinfection Participant must understand oral and written information Participant must not use selenium supplementation of above 50 mcg/d Participant must give written consent prior to inclusion</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>selenium</keyword>
	<keyword>selenium supplementation</keyword>
	<keyword>randomised controlled trial</keyword>
	<keyword>prevention</keyword>
</DOC>